Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that Matti Masanovich has been named Senior Vice President & Chief Financial Officer, effective July 5, 2023. Prior to joining Catalent, Mr. Masanovich served as Executive Vice President & Chief Financial Officer of Tenneco Automotive until it was acquired by Apollo. Previously he was Chief Financial Officer at Super.

Catalent Appoints Matti Masanovich Senior Vice President & Chief Financial Officer

Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Catalent (CTLT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Catalent, Inc. (NYSE:CTLT ) Q3 2023 Earnings Conference Call June 12, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations Alessandro Maselli - President and Chief Executive Officer Ricky Hopson - Interim Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Tejas Savant - Morgan Stanley Dave Windley - Jefferies Luke Sergott - Barclays Sean Dodge - RBC Capital Markets Jack Meehan - Nephron Research Mike Ryskin - Bank of America Max Smock - William Blair John Sourbeer - UBS Operator Good morning and welcome to the Catalent, Inc. Third Quarter Fiscal Year 2023 Earnings Conference Call. My name is Carla and I will be coordinating your call today.

Catalent, Inc. (CTLT) Q3 2023 Earnings Call Transcript

Catalent (CTLT) records lower revenues in both segments in third-quarter fiscal 2023, resulting in overall soft performance.

Catalent (CTLT) Tops Q3 Earnings Estimates, Cuts FY23 View

Catalent shares rose by double digits on Monday after the contract drug maker reported a third-quarter fiscal 2023 revenue beat, despite swinging to a loss and slashing its fiscal 2023 outlook for sales and profit. For the quarter ended March 31, 2023, Catalent posted revenue of $1.04 billion, down 19% from the year-ago quarter but ahead of the Street's expectation of $952.7 million.

Catalent shares rise as 3Q revenue beat overshadows revised outlook

Catalent reports an adjusted loss of 9 cents a share in its fiscal third quarter on revenue of $1.04 billion.

Catalent Cuts Outlook After Releasing Delayed Earnings. The Stock Rises.

Catalent (CTLT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to earnings of $1.04 per share a year ago.

Catalent (CTLT) Reports Q3 Loss, Tops Revenue Estimates

Catalent Inc on Monday posted a bigger-than-expected loss for the third quarter and cut its annual forecast for a second time, hurt by persistent production challenges at the contract drug manufacturer's major facilities.

Catalent posts bigger-than-expected loss as production snags persist

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the third quarter of fiscal 2023, which ended March 31, 2023. “We continue to make progress in addressing our previously announced operational challenges, while also completing our strategic investments in high-demand, high-growth areas and executing a company-wide cost-reduction plan,” said Alessandro.

Catalent, Inc. Reports Third Quarter Fiscal 2023 Results

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financial results for the third quarter of fiscal year 2023 ended March 31, 2023, before the market open on Monday, June 12, 2023. The Company's management will host a webcast to discuss the results at 8:15 a.m. ET on the same day. Catalent invites all interested parties to listen to the webcast and view.

Catalent, Inc. Announces Third Quarter Fiscal Year 2023 Earnings Conference Webcast

Catalent's (CTLT) expansion of its OneBio Suite across multiple biologic therapies is expected to aid customers in leveraging its end-to-end capabilities in these areas.

Catalent (CTLT) Launches Expanded OneBio Suite to Aid Customers

Chipotle

Intel

NVIDIA

Warner Bros Discovery Inc

May was only a so-so month for most S&P 500 investors. But some investors who hit the tech-stock boom just right this month did really well.

Five Stocks Turn $10,000 To $44,175 In Five Months

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.

Catalent (CTLT) Expands Its Facility Capabilities in Shiga

The specialty healthcare company gets another piece of bad news. But this was comparatively mild when judged against other recent developments.

Why Catalent Stock Could Only Inch Higher Today

Catalent shares jumped after the contract drug maker said customer supplies are strong and it's getting "significant" new business.

Catalent Shares Climb After Positive Comments About the Firm's Business

Struggling biotechnology specialist Catalent (NYSE: CTLT ) popped significantly higher on Friday despite poor financial performances and prognostications. Nevertheless, management helped soothe nerves by providing an update on the situation.

Catalent (CTLT) Stock Surges Despite Second Earnings Delay

Invesco Dynamic Biotechnology & Genome ETF

Shares of Catalent (CTLT) are surging on Friday after the contract pharmaceuticals manufacturer provided an update on its full-year outlook and past-due financials. Catalent stock is up over 17% in early trading, making it the top performer in the S&P 500 on Friday.

PBE Offers Exposure to Surging Catalent Stock

Catalent, Inc. (NYSE:CTLT ) Q3 2023 Business Update Transcript May 19, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations Alessandro Maselli - President & Chief Executive Officer Ricky Hopson - Senior Vice President and Interim Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Jacob Johnson - Stephens Julia Qin - JPMorgan Dave Windley - Jefferies Paul Knight - KeyBanc Derik De Bruin - Bank of America Luke Sergott - Barclays Jack Meehan - Nephron Research Max Smock - William Blair John Sourbeer - UBS Sean Dodge - RBC Capital Markets Justin Bowers - Deutsche Bank Operator Ladies and gentlemen, good morning. My name is Abby, and I will be your conference operator today.

Catalent, Inc. (CTLT) Q3 2023 Business Update Transcript

Catalent trimmed its annual revenue and net income forecasts. The contract drug manufacturer said the cuts were due to operational challenges.

Why Shares of Catalent Were Up Friday

Catalent Inc cut its full-year net revenue forecast on Friday, reflecting operational challenges and higher-than-expected costs after it flagged an over $400 million hit to both its annual sales and core profit forecasts earlier this month.

Catalent cuts annual revenue forecast hurt by operational challenges

Shares of Catalent Inc. CTLT, +0.06% sank 5.2% toward a 4 1/2-year low in premarket trading Friday, after the manufacturer of products used by drug makers and consumer health companies cut its full-year revenue outlook, citing operational challenges and higher costs. The company now expects 2023 revenue of $4.250 billion to $4.350 billion from $4.625 billion to $4.875 billion, which compares with the FactSet consensus of $4.427 billion.

Catalent stock sinks to 4 1/2-year low after revenue, income outlook

Catalent is holding a call Friday to update investors on its business and discuss the delay of its third-quarter results.

Catalent Stock Falls. It Needs More Time to Post Quarterly Figures.

Shares of Catalent Inc. CTLT, +0.06% dove to a 5.9% loss in premarket trading Friday, after the provider of delivery technologies and manufacturing services for drug makers said it has received notice from the New York Stock Exchange (NYSE) that it was not in compliance with listing standards. Just prior to the announcement, the stock was up 3.9%.

Catalent stock reverses to a near 6% loss after NYSE notice of noncompliance with listing standards

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, in light of the circumstances described in the Company's Notification of Late Filing on Form 12b-25 filed on May 11, 2023 (the “Form 12b-25”) with the Securities and Exchange Commission (the “SEC”); the Company's ongoing focus on finalizing its financial statements and other disclosures in.

Catalent to Hold Business Update Call Related to Delay of Third Quarter 2023 Results and Receives NYSE Notice Regarding Late Form 10-Q Filing

Danaher

Vornado Realty Trust

Wynn Resorts

Earnings season has been better than feared, and we highlight two firms offering differing views on the state of the economy. There's also one falling Pharma company that (once again) delayed its Q3 results.

News for Catalent Stock (CTLT)